Navigation Links
New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
Date:5/20/2008

s are working and self-management of dosing, as well as seven other related categories(1). The assessment of overall satisfaction was based on all the eleven ATSM items.

About the Study Design (Abstract A13)

Patient satisfaction was assessed in an open-label study involving 832 patients ages 18 years and older with moderate to severe asthma who were previously treated with ICS(1). After a 10-14 day run-in on previous ICS therapy, patients were randomized 2:1 to receive twice daily treatment with two inhalations of budesonide/formoterol combination therapy pressurized metered-dose inhaler (pMDI) fixed dose at 160/4.5 micrograms (mcg) (N=698) or twice daily treatment with one inhalation of fluticasone/salmeterol combination therapy dry powder inhaler (DPI) at 250/50 mcg (N=350)(1). After one month, patients on budesonide/formoterol combination therapy pMDI fixed dose were randomized 1:1 to continue budesonide/formoterol combination therapy pMDI fixed dose (N=333) or budesonide/formoterol combination therapy adjustable dose (N=330) at either once daily treatment with two inhalations of 160/4.5 mcg, twice daily treatment with two inhalations of 160/4.5 mcg, or twice daily treatment with four inhalations of 160/4.5 mcg for six months. The patients originally treated with fluticasone/salmeterol combination therapy remained on that medication (N=335)(1).

About SYMBICORT

SYMBICORT is a combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older(2). Administered twice daily, SYMBICORT is a combination of two proven asthma medications -- budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long- acting beta2-agonist (LABA)(2). SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma(2).

Important Safety Information

Long acting beta2-adrenergic agonists may increase the risk of asthma- related death. Therefore,
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
2. Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
3. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data
4. Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
5. Top Cancer Hospitals in Denmark and Netherlands First in Europe to Treat Patients With RapidArc(TM) Radiotherapy
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
7. Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008
8. CBI and PharmaVoice Announce Recipients of the Strategic Patient Adherence Awards
9. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
10. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
11. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the ... a company overview at the Nomura Biotechnology Conference on Thursday, ... Boston, MA. A live webcast of ... section of the Company,s website, www.isispharm.com .  A replay ... and will be archived for a limited time. ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
(Date:10/27/2014)... October 27, 2014 The new ... Type (High & Medium), Sub-type (Primary & Secondary), ... Infrastructure & Transportation & Power Generation) - Trends ... GIS market with analysis and forecasting of the ... Data Tables with 52 Figures spread through 146 ...
(Date:10/27/2014)... NEW YORK , Oct. 27, 2014 ... in the recent Ebola concern in the ... for the virus.  The healthcare market researcher said the ... of in vitro diagnostic tests for the detection of ... sensitivity has proved useful.  Kalorama routinely assess the IVD ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... Raptor,Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC ... development division, Bennu,Pharmaceuticals Inc. ("Bennu"), has acquired ... the exclusive worldwide license to EC,Cysteamine, developed ... San Diego, School of Medicine, by way ...
... Dec. 17 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: ... molecular diagnostic,tests for the early detection of ... it has started collecting patient samples,for clinical ... development,ColonSentry(TM)., In June 2006, GeneNews presented ...
... is a new drug being,studied to prevent fractures in ... 3 clinical trial using denosumab were presented,Friday evening at ... from the Seattle Cancer Care Alliance., Denosumab is ... -- specialized cells that break down bone. Because it ...
Cached Biology Technology:Raptor Pharmaceuticals Acquires Orphan Clinical Program 2Raptor Pharmaceuticals Acquires Orphan Clinical Program 3Raptor Pharmaceuticals Acquires Orphan Clinical Program 4Raptor Pharmaceuticals Acquires Orphan Clinical Program 5Raptor Pharmaceuticals Acquires Orphan Clinical Program 6GeneNews initiates patient sample accrual for validation studies of colon cancer blood test 2GeneNews initiates patient sample accrual for validation studies of colon cancer blood test 3New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment 2
(Date:10/29/2014)... Researching the safety of nanoparticles is all the rage. ... topic, examining the question of whether titanium dioxide nanoparticles ... into the body, whether carbon nanotubes from electronic products ... to be or whether nanoparticles in food can get ... Public interest is great, research funds are flowing – ...
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
(Date:10/29/2014)... One kind of stem cell, those referred to as ... There is apparently nothing that differentiates these cells from ... namely they retain the capacity to become stem cells ... liver, an organ that hosts cells that stimulate tissue ... the case of a transplant. Knowledge of the ...
Breaking Biology News(10 mins):Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3MSU partners with Detroit to investigate death scenes 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2
... , , WALL, N.J., Dec. ... BKYI), a leader in finger-based biometric identification solutions, ... world,s most respected security publications, named BIO-key International ... Access Control sub-category Biometrics. , (Logo: ...
... , , , , ... states are spending more on protecting their borders, which ... trafficking. High investment in advanced technology security and IT-based ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , New analysis from Frost & ...
... As soon as babies are born, they are susceptible ... For up to a month, their immune systems aren,t ... often minor, they can lead to serious problems if ... of Missouri researchers have pinpointed a group of depleted ...
Cached Biology News:BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3Researchers work on vaccine to improve immune system in newborns 2
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
Nucleobindin 1 [NUCB1]...
Request Info...
... cells (HSC) are well-characterized tissue-specific stem cells ... responsible for the life-long maintenance of the ... reside in adult bone marrow where hematopoiesis ... be found in cord blood, fetal liver, ...
Biology Products: